Member Info for D-Geeman

Another update, I've copied it to $TLSA:

https://www.lse.co.uk/ShareChat.html?ShareTicker=TLSA.US&share=Tiziana-Life-Sciences-Ltd

Tiziana Life Sciences Ltd.

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a nasal anti-CD3 (foralumab) preclinical study is nearing completion, and that foralumab could offer a novel and effective treatment for long COVID. This innovative approach works by reducing microglial activation, a key factor in the persistent brain inflammation associated with long COVID, thereby addressing the debilitating neurological and psychiatric symptoms many patients face.

Long COVID is a complex and often debilitating complication following COVID-19 infection. It affects millions worldwide, presenting with symptoms such as persistent fatigue, cognitive impairment (“brain fog”), and psychiatric issues like depression. A growing body of evidence highlights that long COVID is linked to sustained brain inflammation and microglial activation, which disrupts normal brain function. PET imaging studies confirm increased microglial activity in individuals suffering from long COVID, underlining the urgent need for targeted therapies.

Previously, Tiziana conducted a human clinical study in patients with mild to moderate COVID-19 where foralumab was nasally administered once a day for 10 consecutive days. Treatment was well-tolerated and produced significant reduction in lung inflammation as assessed by computerized tomography (CT) scanning. The aim of the human study was to assess safety of intranasal Foralumab and evaluate its potential benefits in treating immune hyperactivity and lung inflammation who were outpatients at the Santa Casa de Misericordia de Santos Hospital in Brazil.

Tiziana’s nasal anti-CD3 platform has previously demonstrated efficacy in reducing microglial activation in models of central nervous system (CNS) diseases, including multiple sclerosis (MS) and Alzheimer’s Disease.

“Long COVID has challenged the medical community with its complexity, but targeting microglial activation through nasal anti-CD3 presents a promising therapeutic avenue,” commented Tiziana’s CEO, Ivor Elrifi. “A study in secondary progressive multiple sclerosis showed both clinical improvement and decreased microglial activation via TSPO PET imaging, providing a solid foundation for this Long COVID hypothesis. Importantly, nasal anti-CD3 was well tolerated, with no serious adverse events.”

Headstone suggestions and deletions. Probably a bit obscure but here goes. Guesses anyone, who's buried here?

'It. was'nt. Em. Lool X'.

Icecool, I only put pocket money in last week but thanks very much for mentioning WG elsewhere!

(I hope you're right there too :)

'Fascinating that since the invention of AI everyone’s a genius lol '

I wouldn't say 'everyone' Watching2, as you prove almost daily...

‘What RNS???’

‘

("Hemogenyx Pharmaceuticals" or the "Company")

First-in-Human Treatment with HG-CT-1 for Relapsed or Refractory Acute Myeloid Leukemia

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce the administration of its first-in-human dose of HG-CT-1, its proprietary CAR-T cell therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This marks a major milestone in the Company's clinical development program, demonstrating progress toward delivering a potentially life-saving treatment for AML patients with limited therapeutic options.

Further updates on the clinical trial will be provided in due course.

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:

"We are thrilled to take this critical step in advancing the development of HG-CT-1. This milestone not only validates our years of research and development, but also brings us closer to providing a transformative treatment for patients suffering from relapsed or refractory AML."

’

Have a good weekend Wyn!

And enjoy the new motor when delivered :)

‘ professional qualification as a chartered accountant instead of a certified practicing accountant.’

Someone must have spotted the certificate spelt ‘practiCing’ when should have been practiSing accountant…

'both Gemini and DeepSeek suggested'..

Ice, send it to Novartis, AZ, etc :)

And:

If a stock purchase makes money it's an investment. If you're down it's a gamble...

'Loves a Thursday

Rns !'

One day you might be right watching2 but so far you've been wrong dozens of times. Only bit that's right is that today is indeed a Thursday.

Have more respect for yourself and for your audience; please only post stuff that is insightful in future.

Only been in this share a few hours and with a rather small amount. First impressions are that his stated qualification and real qualification are broadly equivalent so he's gone because of the SP rather than the CV (supports others' 'under the bus' theory).

Https://en.wikipedia.org/wiki/Certified_Public_Accountant Certified Public Accountant (CPA) is the title of qualified accountants in numerous countries in the English-speaking world. It is generally equivalent to the title of chartered accountant in other English-speaking countries. In the United States, the CPA is a license to provide accounting services to the public.

'I know so': do you also know why the delay? I'd be a bit upset myself if I were taking part in the trial and was left waiting, since 18th November 2024..

CJ, I mentioned $TLSA here a week or so ago (I very much doubt people here will feel tempted to buy so not a cross-ramp), but regarding your thoughts on P1B, and perhaps how trials are generally run, TLSA are definitely staggering their dosing. This came out a couple of hours ago. TLSA want to boost their SP to remain compliant with Nasdaq rules, hence the recent flow of info from the company – which makes a change. Shame that AVCT don't seem to want to support their SP in a similar way.

'(TLSA) today announced the dosing of an additional four patients in its Intermediate Size Patient Population Expanded Access (ISPPEA) for patients with non-active secondary progressive multiple sclerosis (na-SPMS) who do not qualify for the ongoing Phase 2a study (NCT06292923)'

Another update, I've copied it to $TLSA:

https://www.lse.co.uk/ShareChat.html?ShareTicker=TLSA.US&share=Tiziana-Life-Sciences-Ltd

Update today:

Tiziana Life Sciences Ltd.

NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the dosing of an additional four patients in its Intermediate Size Patient Population Expanded Access (ISPPEA) for patients with non-active secondary progressive multiple sclerosis (na-SPMS) who do not qualify for the ongoing Phase 2a study (NCT06292923). To date, 14 patients have now been enrolled in the expanded access program. The first 10 patients have all shown either an improvement or stability of disease within 6 months of starting treatment.

The na-SPMS expanded access program allows patients who do not meet the inclusion criteria for the ongoing Phase 2a clinical trial to receive treatment with Tiziana’s investigational therapy, intranasal foralumab. This initiative aims to provide potential therapeutic benefits to individuals who may not otherwise have access to these promising treatments.

Ivor Elrifi, CEO of Tiziana Life Sciences, commented, “We are pleased to reach this milestone of enrolling 14 patients in our na-SPMS expanded access program. This underscores our commitment to addressing the unmet medical needs of patients with na-SPMS, particularly those who are not eligible for our ongoing Phase 2a clinical trial. We remain dedicated to advancing our therapies and look forward to further evaluating their potential through both expanded access and clinical trials.”

Tiziana Life Sciences continues to advance its comprehensive research and development efforts to bring forward novel treatments that have the potential to transform the lives of patients with neuroinflammatory disorders including na-SPMS, Alzheimer’s Disease, and ALS.

Harrogate, looks to be a deleted post, and of course Watching2 was posting around that time...

I read the post but can't remember exactly what it said. It was by https://www.lse.co.uk/profiles/m1rob/

I was distracted as I checked the posting history too and he'd made comments on other shares I hold, comments that turned out to be well founded.

Would be nice to think that DX is doing better than previously anticipated so the need to shift it quickly has reduced.

Wouldn't hurt the SP to tell us this, or indeed hurt the negotiations.

And if DX is doing badly? They ought to to take the punch on the nose as I recall a previous poster put it yesterday.

‘ Wnybore’

But only watching2 can spell like watching2!

Ice, do tell us when it’ll be a good time to buy Wood Group. I kind of trust your intentions..

Well I bought back in.. Not as many as I originally held and cost me more but the other share has gone up so not a problem.

(Sawing Machines?

I once saw a saw that could out saw any other saw I ever saw.)